Zealand Pharma
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Press Release – No. 11 / 2025
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025.
Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/w964yrhw . To receive telephone dial-in information and a unique personal access PIN, please register at https://register-conf.media-server.com/register/BI38dbf0632d0e4bcfa7d2cd384405fa1f. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/investors/events-presentations/.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Contacts
Adam Lange (Investors)
Vice President, Investor Relations
alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
akrassowska@zealandpharma.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Boehringer Ingelheim Limited8.8.2025 21:25:53 CEST | Press release
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
European Investment Bank8.8.2025 18:07:24 CEST | Press release
EIB submits SEC Form 18-K/A Amendment No. 4 - Unaudited Condensed Semi-Annual Financial Statements as at and for the six-month period ended June 30, 2025
European Investment Bank8.8.2025 18:04:10 CEST | Press release
EIB submits Form 18-K/A Amendment No.3 - December 2024 EIB Group Risk Management Disclosure Report
SBM Offshore Amsterdam B.V.8.8.2025 18:01:27 CEST | Press release
FPSO ONE GUYANA producing and on hire
Vaisala Group8.8.2025 17:30:00 CEST | Press release
Vaisala Corporation: Share Repurchase 8.8.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom